J
JIAJIAN MEDICAL
An independent medical service organization providing diagnosis and consultant for hereditary and oncological diseases
About JIAJIAN MEDICAL
Guangzhou Jiajian Medical Testing Co., Ltd., operating as JIAJIAN MEDICAL (amcarelab.com), is a clinical genetics-focused enterprise established in August 2015. The company was co-founded by Dr. Zhang Wei, who serves as CEO, and Professor Lu Guohui, the Chief Medical Officer. Dr. Zhang, a clinical genetics and mitochondrial disease specialist, was a lab director at Baylor College of Medicine in the US before returning to China. His motivation stemmed from recognizing the urgent need for advanced genetic testing applications within China's clinical landscape. Professor Lu is a noted expert in clinical cytogenomics and a key figure in promoting clinical genetic counseling in China. Their complementary expertise in molecular, biochemical, and cytogenetics formed the foundation of the company.
JIAJIAN MEDICAL is strategically positioned in the precision medicine market, with a primary mission to reduce the incidence of birth defects in China. The company's business model integrates clinical testing services with the development and production of in-vitro diagnostic (IVD) kits. It serves medical institutions by providing a comprehensive suite of solutions for genetic disease diagnosis and prevention. Revenue is generated through these diagnostic services and the sale of molecular testing instruments, reagents, and software to hospital clients. This approach supports a 'localization' strategy, empowering hospitals to establish their own clinical genetics departments and conduct testing in-house with JIAJIAN's technology and support, including the AmCare-Seq 2000 gene sequencer.
The core of JIAJIAN's service portfolio is built around a three-tier prevention and control system for birth defects. This includes carrier screening before and during pregnancy, prenatal diagnostics for fetuses, and genetic screening for newborns. The company offers a wide array of genetic tests for single-gene disorders, complex hereditary conditions affecting various systems (neurological, cardiovascular, etc.), and specialized diagnostics for mitochondrial diseases. A key component of its offering is professional genetic counseling, providing essential support and interpretation for clinicians and patients. The company has demonstrated significant financial traction, securing multiple funding rounds, including a substantial Series B+ round of nearly 200 million RMB in June 2022 to fuel the R&D and registration of its testing pipelines.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2022 | $28M | $110M | Jointown Pharmaceutical Group · Guangdong Technology Financial Group · Zhongshan Besen Medical Industry Investment Fund · CICC Kai Tak Innovative Biomedicine Fund | ↗ |
| SERIES B✓Equity / VC | Jan 2020 | $15M | $61M | Qianfeng Yihao Investment Partnership · Guangzhou Xinxing Fund · Jiarui Medical · Green Pine Capital | ↗ |
Growth signals
Latest recorded traffic for JIAJIAN MEDICAL is 490 monthly website visits, down 82.5% over the last three months. JIAJIAN MEDICAL's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
JIAJIAN MEDICAL in the Guangzhou ecosystem
The JIAJIAN MEDICAL office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
- GVGuangdong Medical Valley
- ZCZhongda Venture Capital
Mefund Capital- QCQS Capital
- KIKuimu Investment
Green Pine Capital- QPQianfeng Yihao Investment Partnership
- GFGuangzhou Xinxing Fund
- JMJiarui Medical
- CFCICC Kai Tak Innovative Biomedicine Fund
Jointown Pharmaceutical Group
Guangdong Technology Financial Group- ZFZhongshan Besen Medical Industry Investment Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about JIAJIAN MEDICAL on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See JIAJIAN MEDICAL’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









